Job offer – Research assistant

  Location: UK / home based Position : 40 hours per week / permanent Travel required: 10 days / year (approx.) Gross Salary Range: £28,000– £33,000 depending on experience Starting date: hiring immediately   We are seeking a Research Assistant to support the research activities of the Patient Evidence Department of Myeloma Patients Europe (MPE). Please, send your CV and cover letter at . Applications without a cover letter will be rejected.  The following tasks and core…

Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”

  Myeloma Patients Europe (MPE) held a webinar to summarise the most important AL amyloidosis updates and share patient experiences with therapies like CAR-T and CAEL-101.  The webinar took place on 16th April 2024 and was given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein. Watch the recording below:  

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

  Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search of clinical trials for these conditions and provide to patients, carers and…

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

  Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein, who will share their experiences with new therapies like CAR-T and CAEL-101. If you would…

Sign up for the MPE webinar “Basics of medicines pricing in Europe”

Myeloma Patients Europe (MPE) will hold the webinar “Basics of medicines pricing in Europe” on Thursday 7th March 2024 from 15:00 – 16:30 CET. Through this webinar you will understand the basics of drug pricing (with a focus on high-cost branded medicines) and the processes and policies that influence it. The webinar will be given by Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies and Head of Pharmacoeconomics Department,…

EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation

The European Medicines Agency (the EU medicines regulator) Committee for Medicinal Products for Human Use (CHMP) has today confirmed their earlier recommendation to not renew marketing authorisation for belamaf mafadotin (Blenrep®). The confirmation follows a review of the CHMP decision, requested by the manufacturer GSK. MPE Co-Chief Executive Officer, Kate Morgan, commented: “The final recommendation from the EMA CHMP is a disappointing one. Whilst we understand the limitations from the DREAMM-3 clinical trial data, we…

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to ratify. The decision means that the product is safe and effective to prescribe in myeloma patients in the 27 EU…

MPE launches a report focused on the impact of AL amyloidosis in quality of life

AL amyloidosis is a rare condition and limited research on patient perspectives and needs exists. With the aim to better understand patients’ experiences regarding AL amyloidosis diagnosis and treatment, and how these impact on quality of life, MPE conducted qualitative research and published the report “Health-related quality of life, diagnosis and treatment experiences of AL amyloidosis patients.” According to this report, “receiving a diagnosis of AL amyloidosis can make people feel as if they have…

MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023

Myeloma Patients Europe (MPE) will present as part of the Patient Advocacy Track at the European Society for Medical Oncology (ESMO) Annual Congress. The Congress will be held from 20 to 24 October in Madrid, Spain where the latest data in oncology research and development will be presented. Kate Morgan, MPE Co-Chief Executive Officer, and Lise-lott Eriksson, MPE Board President, will each give a talk during the patient advocacy session, “How to improve access to…